FDA Backs Galleri Blood Test — But Reimbursement Is Where The Real Fight Begins

The Panel Split Tells the Whole Story

The FDA advisory committee didn’t just vote on a cancer blood test — it stumbled over the word “early.” Ten panelists unanimously cleared Galleri’s safety. Six sided with it on effectiveness, four against. On the question of whether benefits outweigh risks, seven said yes and two said no, with one abstention.

The friction was linguistic but it revealed something structural: the test can detect aggressive cancers that other methods miss, but aggression doesn’t always mean early stage. One panelist put it bluntly: “There’s a danger in inaccurate labeling. There’s a public confidence issue.”

This distinction matters because it defines how the test will be used, marketed, and reimbursed — and all three determine whether Galleri becomes a routine medical product or a niche diagnostic that only the wealthy self-pay for.

Approval Is the Easy Part

FDA approval for Galleri is now seen as likely in late 2026 or early 2027, according to RBC Capital Markets analyst Dan Leonard. The stock has already rewarded that expectation, surging 116% from its February 20 close before hitting trading halts during the panel meeting. A 34% pop on Monday alone showed how dramatically Wall Street recalibrated its odds after the FDA posted relatively benign briefing documents ahead of the vote.

But approval is the regulatory finish line, not the commercial starting gun. Galleri currently sits in the U.S. as a lab-developed test available by prescription only. FDA approval opens the door to Medicare coverage and broader insurance reimbursement — which is where the actual market gets built. Without reimbursement, Galleri remains a $949 test bought by people who can afford it and not much else.

The Downstream Cost Trap

Here is the problem that hasn’t gotten enough attention. Galleri detects circulating tumor DNA — fragments of genetic material shed by cancers into the bloodstream. Not all cancers shed DNA at detectable levels, which means some tumors slip through. But the test is calibrated for sensitivity over specificity, which produces false positives at a meaningful rate.

In Pathfinder 2, Galleri showed a positive predictive value of 60%. That sounds impressive until you account for what happens next: a patient gets a positive result, undergoes expensive follow-up diagnostics, and the cancer isn’t there. The payer — the insurer, ultimately Medicare — foots the bill for every one of those downstream tests.

Ajit Singh, CEO of Harbinger Health, framed the issue directly: “Who’s paying for all the false positives downstream?” The individual might cover the initial screening, but the payer absorbs the cascade of colonoscopies, MRIs, and biopsies triggered by a positive Galleri result. This is not a hypothetical concern. It is the single biggest barrier to reimbursement.

Singh is building his own cancer test for symptomatic patients, a narrower use case he believes will clear regulatory hurdles more cleanly. He expects a constrained authorization, not broad-based approval, and sees the real market lying with the 40 million people whose symptoms are ambiguous but not yet diagnosed.

The Market Is Massive, But Not All of It

The addressable population for multi-cancer early detection screening is enormous. RBC’s Leonard projects an annual testing opportunity exceeding 100 million in the U.S. and 300 million across major global markets at full expansion. The NHS-Galleri trial in the UK showed a 14% reduction in Stage 4 cancer diagnoses among people who were screened, which is the kind of outcome that makes health systems pay attention.

But Leonard also projects just 1 million Galleri tests over five years. His rationale is sober: the self-pay market for high-priced diagnostics is limited, and meaningful health plan coverage won’t arrive before Medicare phases it in. The “structural commercialization hurdles” he flags are the same ones Singh identified — false positives, downstream costs, and payer hesitation.

The data that saved Galleri from the wreckage of its June study miss was its pancreatic cancer detection. Jeffrey Jones of the Deerborne Group recounted a patient whose pancreatic cancer — a disease with a five-year survival rate of just 13% — was caught early through Galleri and who remained alive four years later. That kind of outcome is hard to argue against. But one dramatic case doesn’t build a reimbursement model.

Who Wins, Who Loses

If Galleri gets approved and moves toward reimbursement, the winners are clear. Grail (a Illumina subsidiary) gains access to the largest diagnostic market in medical history. Hospital systems and health plans benefit if the test meaningfully shifts cancer detection to earlier, cheaper-to-treat stages. Patients with aggressive, hard-to-detect cancers like pancreatic and ovarian gain a tool that didn’t previously exist.

The losers are less obvious but equally important. Incumbent screening tests — colonoscopies, mammograms, PSA tests — face an optional competitor that could reduce adherence to established protocols if patients assume a negative Galleri result covers their bases. The panel explicitly warned that Galleri-negative patients should still undergo age-appropriate screenings.

Insurers face a new cost structure: paying for upstream screening tests and the downstream diagnostic cascade rather than absorbing late-stage treatment costs. Whether that balance shifts in their favor depends entirely on whether Galleri reduces late-stage diagnoses at scale, not just in controlled trials.

What Happens Next

The panel will issue its formal recommendation Wednesday. The FDA is not bound by it but historically follows advisory committee guidance. The labeling debate — whether to call it “early detection” or simply “multi-cancer detection” — will shape clinical adoption more than the vote itself. Physicians are cautious about tests with imprecise language attached; payers are even more so.

Medicare coverage decisions typically lag FDA approval by 12 to 18 months. That timeline pushes meaningful market access into 2028 at the earliest. Grail will spend those months negotiating with private insurers, building real-world evidence, and trying to convince health systems that the downstream cost of false positives is outweighed by the upstream benefit of catching deadly cancers earlier.

The technology works. The question — the one that will determine whether Galleri becomes the holy grail of cancer screening or a costly novelty — is whether the economics work for everyone except the person writing the check.